SCHEMBL1104871

SCHEMBL1104871

C=C(O)C(Cc1ccc(N)cc1)OCC

nearest known ligand 0.47

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 19/20 0.47
PPARG P37231 10/20 0.42
PPARD Q03181 11/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4074678 0.83 PPARA (0.66) PPARAPPARGPPARD
SCHEMBL4082095 0.83 PPARA (0.66) PPARAPPARGPPARD
SCHEMBL756057 0.83 PPARA (0.66) PPARAPPARGPPARD
SCHEMBL1104884 0.83 SRR (0.39) PPARAPPARGPPARD
SCHEMBL1104874 0.81 PPARG (0.43) PPARAPPARGPPARD
SCHEMBL4075927 0.79 PPARA (0.49) PPARAPPARGPPARD
SCHEMBL13649255 0.79 PPARA (0.49) PPARAPPARGPPARD
SCHEMBL1856323 0.79 PPARA (0.49) PPARAPPARGPPARD
SCHEMBL1865433 0.78 PPARA (0.48) PPARAPPARGPPARD
SCHEMBL12664322 0.77 TSHR (0.42) PPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9561202-B2 Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field NOGRA PHARMA LIMITED (IE) 2017-02-07 US disclosed
US-20150265562-A1 Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field GIULIANI INTERNATIONAL LIMITED (IE) 2015-09-24 US disclosed
US-20130005813-A1 Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field GIULIANI INTERNATIONAL LIMITED (IE) 2013-01-03 US disclosed
US-8153841-B2 Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field GIULIANI INTERNATIONAL LIMITED (IE) 2012-04-10 US disclosed
US-20090048343-A1 Compounds and Their Salts Specific to the PPAR Receptors and the EGF Receptors and Their Use in the Medical Field NOGRA PHARMA LIMITED (IE) 2009-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150265562-A1 Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field EGFR, ERBB3, FGFR3 PPARA 9/4885PPARG 4/4885PPARD 12/4885
US-20090048343-A1 Compounds and Their Salts Specific to the PPAR Receptors and the EGF Receptors and Their Use in the Medical Field EGFR, ERBB3, FGFR3 PPARA 9/4885PPARG 4/4885PPARD 12/4885
US-20130005813-A1 Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field EGFR, ERBB3, FGFR3 PPARA 9/4885PPARG 4/4885PPARD 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.